TITLE

Potential Interaction between Clopidogrel and Proton Pump Inhibitors

AUTHOR(S)
Howard, Patricia A.; Vacek, James L.
PUB. DATE
December 2009
SOURCE
American Journal of Cardiovascular Drugs;2009, Vol. 9 Issue 6, p353
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Clopidogrel is widely used in patients with acute coronary syndromes and following percutaneous coronary intervention with stent implantation. The antiplatelet action of clopidogrel is felt to be of critical importance for the reduction of abrupt thrombotic occlusion of stents, particularly with drug-eluting devices. When clopidogrel is used alone or in combination with aspirin (acetylsalicylic acid), the benefits of antiplatelet therapy must be weighed against the potential for serious bleeding, particularly gastrointestinal (GI) bleeds. To minimize the risk of GI injury, proton pump inhibitors (PPIs) are considered the drugs of choice. However, a growing body of evidence suggests that PPIs may adversely interact with clopidogrel, diminishing the antiplatelet effect. Although the current evidence remains controversial, the potential for increased risk of thrombotic complications warrants cautious use of this drug combination until further research can determine the extent of this interaction and whether it is a drug-class effect.
ACCESSION #
48122983

 

Related Articles

  • Antiplatelet therapy for secondary prevention of coronary artery disease. Pilgrim, Thomas; Windecker, Stephan // Heart;Nov2014, Vol. 100 Issue 22, p1750 

    The choice and duration of antiplatelet therapy for secondary prevention of coronary artery disease (CAD) is determined by the clinical context and treatment strategy. Oral antiplatelet agents for secondary prevention include the cyclo-oxygenase-1 inhibitor aspirin, and the ADP dependent P2Y12...

  • Proton Pump Inhibitors and the Prevention of Recurrent GI Bleed in Patients Treated with Clopidogrel. Oyetayo, O.O.; Farris, C.A.; Wahawisan, J. // Clinical Medicine Insights: Therapeutics;2012, Issue 4, p9 

    Clopidogrel is an antiplatelet agent indicated in the management of atherothrombotic conditions. Bleeding is a predictable adverse event associated with antiplatelet agents. While non-ulcerogenic; a major site of bleeding with clopidogrel is the gastrointestinal (GI) tract. The risk of GI...

  • Ticagrelor: a guide to its use in the management of acute coronary syndromes. Scott, Lesley J.; Deeks, Emma D. // Drugs & Therapy Perspectives;Jan2012, Vol. 28 Issue 1, p1 

    The article reports on the pharmacokinetics and tolerability profile of the drug ticagrelor, an oral antiplatelet agent which is used for the prevention of atherothrombotic events in adults with acute coronary syndromes. A discussion of research which investigated the efficacy of ticagrelor is...

  • Ticagrelor: An oral, non-thienopyridine P2Y12 receptor antagonist for the treatment of acute coronary syndromes. Jennings, Douglas L. // Formulary;May2010, Vol. 45 Issue 5, p148 

    Coronary heart disease and acute coronary syndromes (ACS) are a significant cause of morbidity and mortality in the United States. The cornerstone of ACS management is combination oral antiplatelet therapy, usually with aspirin and a thienopyridine. Clopidogrel, the most commonly used...

  • Pharmacogenetic approach to clopidogrel resistance: recurrent stent thrombosis in two brother. Minareci, Edibe; Er, Arzu; Minareci, Kenan // Medical Journal of Suleyman Demirel University;2014, Vol. 21 Issue 2, p58 

    Clopidogrel, is the antiplatelet treatment choice for prevention of thrombosis after coronary stent implantation. However, despite the use of clopidogrel, a considerable number of patients continue to have stent thrombosis. There is a growing degree of evidence that recurrence of ischemic...

  • "My patient has a coronary stent": concerns for the anaesthetist. Lines, D. // South African Family Practice;May/Jun2013, Vol. 55 Issue 3, pS13 

    The article discusses the complications of percutaneous coronary intervention (PCI) in treating patients with coronary artery disease (CAD). A case study of a 56-year-old patient who underwent local clot lysis due to in-stent thrombosis is presented. Particular focus is given to understanding...

  • Antiplatelet therapy for secondary prevention of coronary artery disease. Pilgrim, Thomas; Windecker, Stephan // Postgraduate Medical Journal;May2015, Vol. 91 Issue 1075, p284 

    The choice and duration of antiplatelet therapy for secondary prevention of coronary artery disease (CAD) is determined by the clinical context and treatment strategy. Oral antiplatelet agents for secondary prevention include the cyclo-oxygenase-1 inhibitor aspirin, and the ADP dependent P2Y12...

  • Clopidogrel Bisulfate: A Review of its Use in the Management of Acute Coronary Syndrome. Rossini, Roberta; Musumeci, Giuseppe; Nijaradze, Tamar; Gavazzi, Antonello // Clinical Medicine: Therapeutics;2009, Issue 1, p899 

    Antiplatelet therapy is the cornerstone in the modern therapy of patients with acute coronary syndromes (ACS), because of the unique role of platelets in coronary thrombosis. Clopidogrel in combination with aspirin is the current "gold standard" for reducing cardiovascular events in such...

  • Correction.  // Heart;Jul2015, Vol. 101 Issue 13, p1079 

    A correction to the article "Antiplatelet therapy for secondary prevention of coronary artery disease." that was published in the 2015 issue is presented.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics